Vida Tablet 50mg
10 tablets
Vida 50
Vidagliptin Tablet
Presentation:Vida 50 Each film coated tablet contains Vidaleen INN 50 mg.
Description
Vida" tablet contains the active ingredient Vildagiotin, which is a type of medione called a dipeptidypeptidase-4 (DPP-4) inhibitor. It is used to treat
type 2 diabetes mellitus
Mode of Action:
Vidagipon works by increasing the amount of two incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are normally produced naturally by the body in response to food intake. Their function is to help control blood sugar (glucose) levels. GLP-1 and GIP have two main actions that help to control blood glucose. Firstly, they stimulate the pancreas to produce insulin in response to increasing levels of glucose in the blood. GLP-1 also reduces the production of glucagon GLP-1 and GIP are normally broken down by an enzyme in the body caled dipeptidyl peptidase-4) (DPP-4) Vildagliptin works by binding to this enzyme and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood
sugar.
Indications:
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus. As dual oral therapy in combination with Metformin, in patients with insufficient glycaemic control desple maximal tolerated dose of monotherapy with Metformin,
A sulphonylurea, in patients with insufficient glycaemic control desple maximal tolerated dose of a sulphonylurea and for whom Metformin is Inappropriate due to contraindications or intolerance
A thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a tazolidinedione is appropriate
Dosage & Administration:
When used in dual combination with Metformin, a thiazolidinedione, the recommended dose of Vildagliptin is 50 mg or 100 mg daily. The 50 mg dose should be administered once daily in the moming The 100 mg dose should be administered as two divided doses of 50 mg given in the morning and
evening
When used in dual combination with a sulphonylurea, the recommended dose of Vidagliptin is 50 mg once daily administered in the morning Doses greater than 100 mg are not recommended Vidagipon can be
administered with or without a meal.
Side-effects:
Nausea, peripheral oedema, headache, tremor, asthenia, dizziness, less commonly constipation, hypoglycaemia, rarely upper respiratory tract infection and arthralgia also reported
Use in Pregnancy & Lactation: Pregnancy
Pregnancy category B3. There is no adequate and well-controled studies in pregnant women. Vildagliptin should not be used during pregnancy uniess the benefit to the mother outweighs the potential risk to the foetus.
Lactation
As it is not known whether Vildagliptin is excreted in human milk, Vildagliptin should not be
administered to breastfeeding mother.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients.
Precautions & Warnings:
Vildagliptin is not a substitute for insulin in insulin-requiring patients. Vildagliptin should not be used in patients with type diabetes or for the treatment of diabetic ketoacidosis
Renal impairment. There is limited experience in patients with moderate to severe renal impairment or in patients with end stage renal disease on haemodialysis. Therefore, the use of Vildagliptin is not recommended in these patients.
Hepatic impairment. Vildagliptin should not be used in patients with hepatic
impairment.
Drug Interactions:
Vildagliptin has a low potential for drug interaction. Since Vildagliptin is not a cytochrome (CYP) P450 enzyme substrate and does not inhibit or induce
CYP P450 enzymes, it is not likely to interact with the concomitant medications that are substrates, inhibitors or inducers of these enzymes.
How Supplied:
Vida* 50 Tablet: Each box contains 3x10's tablets in alu-alu blister packs
Manufactured by
PACIFIC PHARMACEUTICALS LTD.
PACIFIC Kanchpur, Narayangonj,Bangladesh.